source
- Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 7d ago↗ source
- Novartis reports nine cancer cases in patients treated with Zolgensma gene therapyNovartis disclosed that nine individuals with spinal muscular atrophy who received its gene therapy Zolgensma later developed tumors. Two of the cases showed evidence that the adeno-associated vir…